CompletedNCT02133001
Esketamine Added to Standard Care for Severe Depression and Imminent Suicide Risk
About this title
A Double-blind Study to Assess the Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Participants Who Are Assessed to be at Imminent Risk for Suicide
Read the official source — NCT02133001This study evaluated the safety and effectiveness of Esketamine for people with depression.
Medication studyAges 18–64United States
Understand this study
What did researchers investigate?
This study evaluated the safety and effectiveness of Esketamine for people with depression.
Who was this study for?
Listed age limits: 18 years to 64 years.
- Listed locations
- Birmingham and 13 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateStarted: May 23, 2014
- Recruitment status
- Completed
- Enrollment listed in the registry
- 68
- Sponsor
- Janssen Research & Development, LLC
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 64 Years
- Official registry ID
- NCT02133001
- Official title
Show the full official title
A Double-blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Subjects Who Are Assessed to be at Imminent Risk for Suicide
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Birmingham · San Diego · Hartford
11 more locations
- New Haven
- Atlanta
- Iowa City
- Baltimore
- Towson
- Ann Arbor
- Rochester
- Cincinnati
- Philadelphia
- Pittsburgh
- Houston
Interested in joining this study?
Questions about this study
What did researchers investigate?
This study evaluated the safety and effectiveness of Esketamine for people with depression.
Who is behind this study?
The study sponsor is Janssen Research & Development, LLC.
Did this study involve medication?
Yes. The study involved medication, including Esketamine and Placebo.
Who was this study for?
Listed age limits: 18 years to 64 years.
